(BHC) Bausch Health Companies Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BHC) Bausch Health Companies Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This Bausch Health Companies Inc. BCG Matrix is a company-specific strategy tool used to assess products or business units across the Stars, Cash Cows, Question Marks, and Dogs framework. The page already includes a real preview of the actual analysis, so you can see the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Lumify, U.S. OTC eye redness brand
Lumify, launched in 2018, sits in the large U.S. OTC eye-redness market, where demand keeps expanding with everyday use. Bausch + Lomb’s wide retail reach and strong brand recall help drive repeat buys, while premium pricing supports margins. That mix of growth, scale, and sticky demand fits a Star profile.
Solta Medical, global aesthetics devices
Solta Medical sells energy-based aesthetics systems such as Thermage, Fraxel, and Clear + Brilliant across North America, Europe, and Asia-Pacific. The medical aesthetics devices market kept growing in 2025, led by rising elective skin-treatment demand and repeat use. With 3 flagship brands and stronger growth than Bausch Health's mature units, Solta fits the Star quadrant.
Bausch + Lomb surgical ophthalmology platform
Bausch + Lomb's surgical ophthalmology platform sells cataract and other eye-surgery products into a specialized market with recurring placements and sticky surgeon relationships. Global demand stays strong as populations age; the WHO said 1.1 billion people were age 60+ in 2024, a base that keeps lifting procedure volumes. Its established share in this growing niche fits a Star in the BCG Matrix.
Bausch + Lomb premium contact lenses, ULTRA and INFUSE
Bausch + Lomb’s ULTRA and INFUSE fit a Star in Bausch Health Companies Inc.’s BCG matrix: premium contact lens demand keeps shifting toward comfort, and Bausch + Lomb has broad global reach, strong brand depth, and wide distribution in eye care. That mix supports growth and share gains in a higher-value category.
- Premium comfort lenses keep trading up
- Global eye-care footprint supports scale
- Brand depth helps repeat buying
- Distribution widens market access
Miebo, dry-eye prescription drop
Miebo, approved in the U.S. in May 2023, is a newer drug in a dry-eye market that affects about 38 million U.S. adults, so the runway is still long. Dry-eye diagnosis and treatment are rising, which supports growth. Early launches need heavy doctor promotion, payer access, and patient education, but that is normal for a new category entrant.
For Bausch Health Companies Inc., Miebo fits the Star box: high-growth market, early uptake, and room to scale if access improves. The key watchpoint is whether Bausch + Lomb can turn launch spend into durable prescription growth.
- U.S. approval: May 2023
- Market size: about 38 million adults
- Stage: early commercialization
- BCG view: Star potential
Bausch Health’s Stars Shine in Expanding Eye-Care and Aesthetics Markets
Bausch Health Companies Inc.’s Stars are Lumify, Solta Medical, surgical ophthalmology, ULTRA and INFUSE, and Miebo. They sit in growing markets: dry eye affects about 38 million U.S. adults, the world had 1.1 billion people aged 60+ in 2024, and 2025 aesthetics and eye-care demand kept rising. Strong brands, broad distribution, and repeat use support share gains.
| Star | Signal |
|---|---|
| Miebo | Dry-eye growth |
| Solta Medical | 2025 demand rise |
| Lumify | OTC scale |
What is included in the product
Detailed Word Document
Bausch Health’s BCG Matrix maps its portfolio to spot Stars, Cash Cows, Questions, and Dogs for invest, hold, or divest calls.
Editable Excel File
Bausch Health BCG Matrix: one-page quadrant view that quickly spots pain points and growth bets.
Reference Sources
Provides a credible source trail for Bausch Health Companies Inc., helping verify key claims quickly and strengthening decision-making confidence.
Cash Cows
Xifaxan, U.S. GI franchise
Xifaxan is Bausch Health Companies Inc.'s flagship GI brand, and 2024 net sales were about $1.1 billion. Demand is long-standing and the U.S. GI market is mature, so growth is limited. That mix of high cash generation and low growth is classic Cash Cow territory.
PreserVision AREDS 2, eye vitamin leader
PreserVision AREDS 2 is a mature, repeat-buy OTC eye vitamin brand in age-related eye health, so it fits the Cash Cow box well. Bausch Health Companies Inc. does not break out PreserVision revenue separately in recent public reporting, but the brand’s long shelf life, strong recognition, and pharmacy placement support steady 2025 cash flow. With low innovation needs and a stable, aging customer base, it keeps generating cash rather than consuming it.
Jublia, toenail fungus treatment
Jublia is Bausch Health Companies Inc.'s established toenail fungus brand, approved in 2014 and still selling through long prescription history and brand recall. In Bausch Health Companies Inc.'s 2025 filings, the dermatology segment remained a steady contributor even as growth slowed versus newer launches. Its niche market and mature demand fit a Cash Cow profile: low growth, durable sales, and reliable cash generation.
Lotemax and Alrex, ophthalmic steroid brands
Lotemax and Alrex are long-running prescription ophthalmic steroids with clear use cases, so they fit Bausch Health Companies Inc.'s Cash Cow bucket. Their market is mature, not fast-growing, and Bausch Health can keep serving repeat demand with relatively low added investment. Public filings do not break out brand-level 2025/2026 revenue, but the steady eye-care cash flow pattern is exactly what a Cash Cow looks like.
- Established, narrow prescription use
- Low growth, stable demand
- Recurring revenue, modest reinvestment
- Strong Cash Cow profile
Biotrue, mature eye-care consumer line
Biotrue is a mature lens-care and eye-health line sold through retail, so it sits in Bausch Health Companies Inc.’s Cash Cow bucket: high share, low growth, and steady cash generation. Its strength is Bausch + Lomb’s broad distribution scale, which helps keep shelf presence and repeat purchases stable. Growth is not fast, but the franchise still supports dependable volume and margin mix.
- Retail lens care and eye-health brand
- Mature, steady demand profile
- Backed by Bausch + Lomb scale
- Fits low-growth, high-share Cash Cow
Bausch’s Cash Cows: Xifaxan Leads the Pack
Xifaxan led Bausch Health Companies Inc. cash cows, with 2024 net sales near $1.1 billion, while PreserVision, Jublia, Lotemax/Alrex, and Biotrue stayed in mature, repeat-use niches. These brands share low growth, strong recognition, and limited reinvestment needs, so they keep throwing off cash instead of burning it. That is the core Cash Cow profile.
| Brand | Signal |
|---|---|
| Xifaxan | $1.1B sales |
| PreserVision | Stable OTC demand |
| Jublia | Mature Rx niche |
Preview the Actual Deliverable
Bausch Health Companies Inc. Reference Sources
You’re previewing the actual Bausch Health Companies Inc. BCG Matrix report you’ll receive after purchase. The document is identical to the final file—no demo pages, no placeholders, and no hidden changes. It’s ready for immediate download, review, or use in your strategic analysis. Buy once and get the complete, professional version.
Dogs
Relistor, opioid-induced constipation brand
Relistor remains a Dog in Bausch Health Companies Inc.’s BCG Matrix because it serves a narrow opioid-induced constipation niche and has not scaled into a broad-market brand. Sales rely on a specialized prescriber base, while competition from other constipation therapies keeps growth capped. That limited reach makes Relistor less attractive than Bausch Health Companies Inc.’s larger franchise assets.
Siliq, psoriasis biologic
Siliq, a psoriasis biologic from Bausch Health Companies Inc., stays a niche brand in a crowded market with many larger rivals. It has not reached scale, and uptake has stayed well below leading dermatology biologics.
That makes it a classic low-share, low-growth asset in the BCG matrix. In a category where top brands dominate prescriptions and payer access, Siliq has remained a small player.
Duobrii, topical psoriasis therapy
Duobrii sits in a crowded topical psoriasis market, where generics, steroids, and nonsteroid creams keep pricing and share tight. Bausch Health Companies Inc. has not shown Duobrii as a high-scale growth driver, and its commercial push has not converted into meaningful market depth. With limited growth and no clear path to large share, it fits the Dog quadrant.
Bryhali, topical corticosteroid
Bryhali 0.01% is a topical corticosteroid for plaque psoriasis, a narrow dermatology niche where low-cost generics and newer biologics keep pricing and volume pressure high. With limited label breadth and no clear 2025 momentum, it fits a Dog in Bausch Health Companies Inc.'s BCG mix.
- 0.01% topical steroid
- Small, niche psoriasis use
- Competitive, mature category
- Limited 2025 growth signal
Legacy generics and dental products
Legacy generics and dental products fit Dogs because they are mature, fragmented lines with weak differentiation and low pricing power. In Bausch Health Companies Inc., these businesses usually earn modest returns while capital stays tied up in inventory, plants, and compliance. That makes cash generation limited versus the capital base.
Generic drug prices keep falling as competition rises, and dental products face the same squeeze from commoditized demand. For Bausch Health Companies Inc., that means these lines are better viewed as cash harvest assets than growth engines.
- Low pricing power
- Fragmented, mature markets
- Modest return on capital
- Best fit: Dog
Bausch Health’s Dogs: Harvest, Don’t Grow
Dogs in Bausch Health Companies Inc.’s BCG mix are Relistor, Siliq, Duobrii, Bryhali 0.01%, and mature generics and dental lines. They sit in slow or crowded niches, with weak share and limited 2025 growth. That keeps pricing power low and cash returns modest. Bausch Health Companies Inc. should treat them as harvest assets, not growth engines.
Question Marks
Trulance, U.S. constipation and IBS-C brand
Trulance, approved by the U.S. FDA in 2017, sits in a growing GI market, but it still trails better-known rivals like Linzess, so Bausch Health Companies Inc. has not built dominant share. That fits a Question Mark: the category can expand, but Trulance needs much more scale to turn growth into a leadership position.
Xiidra, dry-eye prescription therapy
Xiidra sits in a large dry-eye market that keeps growing; the U.S. has about 16 million diagnosed dry-eye patients, and prescription demand is still expanding. But competition from Restasis, Cequa, Miebo, and OTC drops keeps share from becoming clearly dominant. That means Xiidra has upside, yet it still needs steady marketing and access spend to defend and grow prescriptions, which fits Question Mark territory.
Vyzulta, glaucoma therapy
Vyzulta competes in a chronic glaucoma market serving about 80 million people worldwide in 2020, with demand set to reach 111.8 million by 2040.
It is a once-daily prostaglandin option, but its share still trails top leaders like latanoprost, so Bausch Health Companies Inc. has not turned it into a category winner.
That keeps Vyzulta in the Question Mark box: the market is large and sticky, but growth depends on stronger adoption and better sales execution.
Arazlo, acne topical
Arazlo, Bausch Health Companies Inc.’s 0.045% tazarotene acne lotion, sits in a growing prescription acne market, but it is still early in its life cycle and must win physician habit one script at a time. Competitive pressure is heavy from entrenched topical retinoids and combination therapies, so the brand has not yet earned a clear share lead. That keeps Arazlo in the Question Mark box.
- 0.045% tazarotene strength
- Newer brand, still gaining adoption
- High competition keeps risk elevated
Cabtreo, acne combination gel
Cabtreo, launched in 2023, fits a Question Mark because it entered a large, still-growing acne market but has not yet built meaningful share. Early products like this usually need heavy promotion, payer access work, and formulary wins before sales scale. Its value depends on how fast Bausch Health can turn first use into repeat prescriptions.
- 2023 launch; share still building.
- Needs strong promotion and access.
- Upside depends on Rx momentum.
Bausch Health’s Brands Have Upside, But Share Gains Are the Key
Bausch Health Companies Inc.’s Question Marks have clear upside, but they still need share gains. Trulance, Xiidra, Vyzulta, Arazlo, and Cabtreo each sit in large or growing markets, yet none has dominant scale.
| Brand | Signal |
|---|---|
| Trulance | GI growth, weak share |
| Xiidra | 16M U.S. dry-eye patients |
| Vyzulta | 111.8M glaucoma by 2040 |
| Cabtreo | 2023 launch, early share |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.